CPA
CCCC icon

Capital Performance Advisors’s C4 Therapeutics CCCC Stock Holding History

Capital Performance Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-54
Closed -$308 – 601
2024
Q3 		$308 Buy
+54
New +$325 ﹤0.01% 2451

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Performance Advisors's CCCC Position: Q4 2024 in Review

Capital Performance Advisors sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 54 shares — an estimated $308 sold.

Capital Performance Advisors first reported a position in CCCC in Q3 2024 and held it in 1 quarter. The position peaked at $308 in Q3 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Capital Performance Advisors reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 54 C4 Therapeutics shares in Q4 2024, an estimated $308.
  • Capital Performance Advisors first reported a position in C4 Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's C4 Therapeutics position peaked at $308 in Q3 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.